CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden Journal Article
| Authors: | Peterfy, C.; Chen, Y.; Countryman, P.; Chmielowski, B.; Anthony, S. P.; Healey, J. H.; Wainberg, Z. A.; Cohn, A. L.; Shapiro, G. I.; Keedy, V. L.; Singh, A.; Puzanov, I.; Wagner, A. J.; Qian, M.; Sterba, M.; Hsu, H. H.; Tong-Starksen, S.; Tap, W. D. |
| Article Title: | CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden |
| Abstract: | Aim: Monitoring treatment of tenosynovial giant cell tumor (TGCT) is complicated by the irregular shape and asymmetrical growth of the tumor. We compared responses to pexidartinib by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with those by tumor volume score (TVS) and modified RECIST (m-RECIST). Materials & methods: MRIs acquired every two cycles were assessed centrally using RECIST 1.1, m-RECIST and TVS and tissue damage score (TDS). Results: Thirty-one evaluable TGCT patients were treated with pexidartinib. From baseline to last visit, 94% of patients (29/31) showed a decrease in tumor size (median change: -60% [RECIST], -66% [m-RECIST], -79% [TVS]). All methods showed 100% disease control rate. For TDS, improvements were seen in bone erosion (32%), bone marrow edema (58%) and knee effusion (46%). Conclusion: TVS and m-RECIST offer potentially superior alternatives to conventional RECIST for monitoring disease progression and treatment response in TGCT. TDS adds important information about joint damage associated with TGCT. © 2022 Charles Peterfy. |
| Keywords: | nuclear magnetic resonance imaging; magnetic resonance imaging; tumor volume; diagnostic imaging; tumor burden; recist; mri; response evaluation criteria in solid tumors; tenosynovial giant cell tumor; colony stimulating factor receptor; receptor, macrophage colony-stimulating factor; humans; human; modified recist; pexidartinib; giant cell tumor of tendon sheath; tissue damage score; tumor volume score |
| Journal Title: | Future Oncology |
| Volume: | 18 |
| Issue: | 12 |
| ISSN: | 1479-6694 |
| Publisher: | Future Medicine |
| Date Published: | 2022-04-01 |
| Start Page: | 1449 |
| End Page: | 1459 |
| Language: | English |
| DOI: | 10.2217/fon-2021-1437 |
| PUBMED: | 35040698 |
| PROVIDER: | scopus |
| PMCID: | PMC11197039 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 May 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work